Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin - Boulton, David; Li, Li; Frevert, Ernst U.; Tang, Angela; Castaneda, Lorna; Vachharajani, Nimish N.; Kornhauser, David M.; Patel, Chirag G. (Clinical pharmacokinetics, 2011)
Keywords: Adamantane - adverse effects; Adamantane - analogs & derivatives; Adamantane - analysis; Adamantane - blood; Adamantane - pharmacokinetics; Adamantane - urine; Adult; Aged; Biological and medical sciences; Complications and side effects; Diabetes Mellitus, Type 2 - drug therapy; Dialysis Solutions - chemistry; Dipeptides - adverse effects; Dipeptides - analysis; Dipeptides - blood; Dipeptides - pharmacokinetics; Dipeptides - urine; Dipeptidyl-Peptidase IV Inhibitors - adverse effects; Dipeptidyl-Peptidase IV Inhibitors - analysis; Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics; Dosage and administration; Female; Gastroenterology. Liver. Pancreas. Abdomen; General pharmacology; Half-Life; Hepatic Insufficiency - blood; Hepatic Insufficiency - metabolism; Hepatic Insufficiency - urine; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - analysis; Hypoglycemic Agents - pharmacokinetics; Internal Medicine; Kidney Failure, Chronic - blood; Kidney Failure, Chronic - metabolism; Kidney Failure, Chronic - therapy; Liver diseases; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Male; Medical sciences; Medicine; Medicine & Public Health; Metabolic Clearance Rate; Middle Aged; Nephrology. Urinary tract diseases; Nephropathies. Renovascular diseases. Renal failure; Original Research Article; Other diseases. Semiology; Pharmacokinetics; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions; Pharmacology. Drug treatments; Pharmacology/Toxicology; Pharmacotherapy; Physiological aspects; Renal Dialysis; Renal failure; Renal Insufficiency - blood; Renal Insufficiency - metabolism; Renal Insufficiency - urine; Saxagliptin; Severity of Illness Index; United States; Normal Renal Function; Severe Renal Impairment; Renal Impairment; Hepatic Impairment; Saxagliptin; Dipeptidyl-peptidase IV; Kidney disease; Human; Urinary system disease; Enzyme; Enzyme inhibitor; Hepatic disease; Peptidases; Hypoglycemic agent; Liver failure; Nephropathy; Gliptine derivatives; Renal failure; Hydrolases; Dipeptidyl-peptidase IV inhibitor; Digestive diseases; Pharmacokinetics